ViroGates A/S
VIRO
Rank in Stocks
#28384
ViroGates A/S is a Danish firm specializing in the creation and... ViroGates A/S is a Danish firm specializing in the creation and commercialization of prognostic diagnostic solutions for the medical field. Its flagship product, suPARnostic, is a blood test designed to quantify the soluble urokinase plasminogen activator receptor (suPAR) protein within a patient's circulatory system. This innovative tool empowers hospital emergency rooms to refine their clinical assessments regarding the admission or release of patients with acute medical conditions, thereby contributing to lower healthcare expenditures. Beyond this, ViroGates also supplies several other suPARnostic variations: suPARnostic TurbiLatex, a specialized latex particle-enhanced turbidimetric immunoassay for precise suPAR quantification in specific human plasma samples (K2-EDTA or lithium heparin); the suPARnostic Quick Triage kit, optimized for rapid early warning and patient categorization at the point of care; and suPARnostic ELISA, which delivers comprehensive quantitative readings. The prognostic capabilities of suPAR extend across a broad spectrum of medical conditions, encompassing cardiovascular, renal, oncological, diabetic, hepatic, infectious, respiratory, and rheumatic diseases. Established in 2000, the company maintains its headquarters in Birkerød, Denmark.
Share Price
$1.24
Last synced: 2026-11-09
Market Cap
$11.27M
Change (1 day)
6.47%
Change (1 year)
-33.76%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade ViroGates A/S (VIRO)
Category
Healthcare
Operating Margin for ViroGates A/S (VIRO)
Operating Margin as of November 2026 TTM: -107.05%
According to ViroGates A/S's latest financial reports, its current operating margin (TTM) is -107.05%. At the end of 2025 the company had an operating margin of -265.10%.
Operating Margin history for ViroGates A/S from 2015 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -107.05% | -59.62% |
| 2025 | -265.10% | -22.75% |
| 2024 | -343.17% | 90.83% |
| 2023 | -179.83% | 152.00% |
| 2022 | -71.36% | -70.92% |
| 2021 | -245.42% | -33.40% |
| 2020 | -368.49% | -33.08% |
| 2019 | -550.61% | 0.86% |
| 2018 | -545.90% | 73.24% |
| 2017 | -315.12% | 67.44% |
| 2016 | -188.20% | 26.25% |
| 2015 | -149.07% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 15.24% | -100.14% |
US
|
|
| 18.08% | -100.17% |
IE
|
|
| 21.25% | -100.20% |
US
|
|
| 21.05% | -100.20% |
US
|
|
| 28.09% | -100.26% |
US
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about ViroGates A/S's operating margin
What is ViroGates A/S's operating margin?
ViroGates A/S's operating margin is -107.05%, as of Nov 2026.
What was ViroGates A/S's operating margin in 2025?
In 2025, ViroGates A/S's operating margin was -265.10%, compared with -343.17% in 2024.
How has ViroGates A/S's operating margin changed since 2020?
From 2020 to 2025, ViroGates A/S's operating margin was highest in 2022 (-71.36%) and lowest in 2020 (-368.49%).
How does ViroGates A/S's operating margin compare with similar companies?
ViroGates A/S's operating margin (-107.05%) is lower than that of all 5 similar companies listed above. The highest among them is Edwards Lifesciences Corporation, with 28.09%.